These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 19850771)

  • 1. Chronic calcineurin inhibitor nephrotoxicity: reflections on an evolving paradigm.
    Gaston RS
    Clin J Am Soc Nephrol; 2009 Dec; 4(12):2029-34. PubMed ID: 19850771
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Calcineurin inhibitor nephrotoxicity: a review and perspective of the evidence.
    Issa N; Kukla A; Ibrahim HN
    Am J Nephrol; 2013; 37(6):602-12. PubMed ID: 23796509
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is arteriolar vacuolization a predictor of calcineurin inhibitor nephrotoxicity?
    Horike K; Takeda A; Yamaguchi Y; Ogiyama Y; Yamauchi Y; Murata M; Kawaguchi T; Suzuki T; Otsuka Y; Inaguma D; Goto N; Watarai Y; Uchida K; Morozumi K
    Clin Transplant; 2011 Jul; 25 Suppl 23():23-7. PubMed ID: 21623910
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Renal function improves in liver transplant recipients when switched from a calcineurin inhibitor to sirolimus.
    Fairbanks KD; Eustace JA; Fine D; Thuluvath PJ
    Liver Transpl; 2003 Oct; 9(10):1079-85. PubMed ID: 14526403
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ACE gene D/D genotype as a risk factor for chronic nephrotoxicity from calcineurin inhibitors in liver transplant recipients.
    Gallon L; Akalin E; Lynch P; Rothberg L; Parker M; Schiano T; Abecassis M; Murphy B
    Transplantation; 2006 Feb; 81(3):463-8. PubMed ID: 16477235
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
    Schena FP; Pascoe MD; Alberu J; del Carmen Rial M; Oberbauer R; Brennan DC; Campistol JM; Racusen L; Polinsky MS; Goldberg-Alberts R; Li H; Scarola J; Neylan JF;
    Transplantation; 2009 Jan; 87(2):233-42. PubMed ID: 19155978
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus.
    Bumbea V; Kamar N; Ribes D; Esposito L; Modesto A; Guitard J; Nasou G; Durand D; Rostaing L
    Nephrol Dial Transplant; 2005 Nov; 20(11):2517-23. PubMed ID: 15985508
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conversion to sirolimus for chronic allograft nephropathy and calcineurin inhibitor toxicity and the adverse effects of sirolimus after conversion.
    Sayin B; Karakayali H; Colak T; Sevmis S; Pehlivan S; Demirhan B; Haberal M
    Transplant Proc; 2009 Sep; 41(7):2789-93. PubMed ID: 19765436
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of calcineurin inhibitors on graft survival.
    Rush D
    Transplant Rev (Orlando); 2013 Jul; 27(3):93-5. PubMed ID: 23743217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Calcineurin inhibitors in heart transplantation.
    Keogh A
    J Heart Lung Transplant; 2004 May; 23(5 Suppl):S202-6. PubMed ID: 15093806
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Calcineurin nephrotoxicity.
    Williams D; Haragsim L
    Adv Chronic Kidney Dis; 2006 Jan; 13(1):47-55. PubMed ID: 16412970
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Maximizing the clinical outcome with mTOR inhibitors in the renal transplant recipient: defining the role of calcineurin inhibitors.
    Nashan B
    Transpl Int; 2004 Jul; 17(6):279-85. PubMed ID: 15221123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conversion from calcineurin inhibitor to sirolimus for renal function deterioration in kidney allograft recipients.
    Martínez-Mier G; Méndez-López MT; Estrada-Oros J; Budar-Fernandez LF; Soto-González JI; Méndez-Machado GF; Viñas Dozal JC
    Arch Med Res; 2006 Jul; 37(5):635-8. PubMed ID: 16740435
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Calcineurin inhibitor-free immunosuppression in kidney transplantation.
    Guerra G; Srinivas TR; Meier-Kriesche HU
    Transpl Int; 2007 Oct; 20(10):813-27. PubMed ID: 17645419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapamycin rescue therapy in patients after kidney transplantation: first clinical experience.
    Weber T; Abendroth D; Schelzig H
    Transpl Int; 2005 Feb; 18(2):151-6. PubMed ID: 15691266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is acute rejection the key predictor for long-term outcomes after renal transplantation when comparing calcineurin inhibitors?
    Nashan B
    Transplant Rev (Orlando); 2009 Jan; 23(1):47-52. PubMed ID: 19027616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic allograft nephropathy.
    Ponticelli C
    N Engl J Med; 2004 Mar; 350(12):1254-6; author reply 1254-6. PubMed ID: 15028831
    [No Abstract]   [Full Text] [Related]  

  • 18. Untreated rejection in 6-month protocol biopsies is not associated with fibrosis in serial biopsies or with loss of graft function.
    Scholten EM; Rowshani AT; Cremers S; Bemelman FJ; Eikmans M; van Kan E; Mallat MJ; Florquin S; Surachno J; ten Berge IJ; Bajema IM; de Fijter JW
    J Am Soc Nephrol; 2006 Sep; 17(9):2622-32. PubMed ID: 16899517
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primer: Histopathology of calcineurin-inhibitor toxicity in renal allografts.
    Liptak P; Ivanyi B
    Nat Clin Pract Nephrol; 2006 Jul; 2(7):398-404; quiz following 404. PubMed ID: 16932468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Minimization of calcineurin inhibitors to improve long-term outcomes in kidney transplantation.
    Golshayan D; Pascual M
    Transpl Immunol; 2008 Nov; 20(1-2):21-8. PubMed ID: 18775494
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.